Table 1.
Characteristics | National Cohort (N=1,187)
|
Regional cohort by cardiac imaging availability (N=539)
|
||||||
---|---|---|---|---|---|---|---|---|
Baseline and Follow-up (N=75)
|
Follow-up only (N=25)
|
None or baseline only (N=439)
|
||||||
N | % | N | % | N | % | N | % | |
Age at diagnosis, years | ||||||||
<40 | 226 | 19.0 | 18 | 24.0 | 8 | 32.0 | 65 | 14.8 |
40–59 | 379 | 32.0 | 33 | 44.0 | 11 | 44.0 | 174 | 39.7 |
60–79 | 461 | 38.9 | 24 | 32.0 | 6 | 24.0 | 164 | 37.3 |
≥80 | 121 | 10.2 | 0 | 0 | 0 | 0 | 36 | 8.2 |
Sex | ||||||||
Female | 535 | 45.1 | 31 | 41.3 | 12 | 48.0 | 207 | 47.2 |
Male | 652 | 54.9 | 44 | 58.7 | 13 | 52.0 | 232 | 52.8 |
STS subtype | ||||||||
Leiomyosarcoma | 381 | 32.1 | 32 | 42.7 | 11 | 44.0 | 147 | 33.5 |
Liposarcoma | 392 | 33.0 | 14 | 18.7 | 3 | 12.0 | 152 | 34.6 |
Synovial sarcoma | 84 | 7.1 | 16 | 21.3 | 3 | 12.0 | 37 | 8.4 |
Angiosarcoma | 80 | 6.8 | 5 | 6.7 | 2 | 8.0 | 22 | 5.0 |
Rhabdomyosarcoma | 74 | 6.2 | 3 | 4.0 | 5 | 20.0 | 10 | 2.3 |
Other | 176 | 14.9 | 4 | 5.3 | 1 | 4 | 60 | 13.7 |
Unclassified | 0 | 0 | 1 | 1.3 | 0 | 0 | 11 | 2.5 |
STS stage at diagnosis | ||||||||
I | – | – | 4 | 5.3 | 0 | 0 | 74 | 16.9 |
II | – | – | 5 | 6.7 | 2 | 8.0 | 62 | 14.1 |
III | – | – | 20 | 26.7 | 5 | 20.0 | 58 | 13.2 |
IV | – | – | 9 | 12.0 | 3 | 12.0 | 25 | 5.7 |
Unknown | – | – | 37 | 49.3 | 15 | 60.0 | 220 | 50.1 |
Treatment type | ||||||||
Chemotherapy | – | – | 75 | 100 | 25 | 100 | 81 | 18.5 |
Radiation | – | – | 49 | 65.3 | 15 | 60.0 | 160 | 36.4 |
Surgery | – | – | 64 | 85.3 | 22 | 88.0 | 416 | 94.8 |
Pre-existing cardiovascular disease | ||||||||
– | – | 31 | 41.3 | 7 | 28.0 | 182 | 41.5 | |
Death after diagnosis | ||||||||
1-year | 197 | 19.6 | 13 | 17.3 | 5 | 20.0 | 51 | 11.6 |
5-year | 447 | 37.7 | 43 | 57.3 | 18 | 72.0 | 131 | 29.8 |
Abbreviations: –, not available; STS, soft tissue sarcoma.